Abstract
Background: Virtual Screening (VS) has emerged as an important tool in the drug development process, as it conducts efficient in silico searches over millions of compounds, ultimately increasing yields of potential drug leads. As a subset of Artificial Intelligence (AI), Machine Learning (ML) is a powerful way of conducting VS for drug leads. ML for VS generally involves assembling a filtered training set of compounds, comprised of known actives and inactives. After training the model, it is validated and, if sufficiently accurate, used on previously unseen databases to screen for novel compounds with desired drug target binding activity.
Objective: The study aims to review ML-based methods used for VS and applications to Alzheimer’s Disease (AD) drug discovery.
Methods: To update the current knowledge on ML for VS, we review thorough backgrounds, explanations, and VS applications of the following ML techniques: Naïve Bayes (NB), k-Nearest Neighbors (kNN), Support Vector Machines (SVM), Random Forests (RF), and Artificial Neural Networks (ANN).
Results: All techniques have found success in VS, but the future of VS is likely to lean more largely toward the use of neural networks – and more specifically, Convolutional Neural Networks (CNN), which are a subset of ANN that utilize convolution. We additionally conceptualize a work flow for conducting ML-based VS for potential therapeutics for AD, a complex neurodegenerative disease with no known cure and prevention. This both serves as an example of how to apply the concepts introduced earlier in the review and as a potential workflow for future implementation.
Conclusion: Different ML techniques are powerful tools for VS, and they have advantages and disadvantages albeit. ML-based VS can be applied to AD drug development.
Keywords: Artificial intelligence, machine learning, drug discovery, virtual screening, k-nearest neighbors, support vector machines, naïve bayes, random forests, artificial neural networks, convolutional neural networks, Alzheimer's disease.
Current Pharmaceutical Design
Title:Machine Learning-based Virtual Screening and Its Applications to Alzheimer’s Drug Discovery: A Review
Volume: 24 Issue: 28
Author(s): Kristy A. Carpenter and Xudong Huang*
Affiliation:
- Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129,United States
Keywords: Artificial intelligence, machine learning, drug discovery, virtual screening, k-nearest neighbors, support vector machines, naïve bayes, random forests, artificial neural networks, convolutional neural networks, Alzheimer's disease.
Abstract: Background: Virtual Screening (VS) has emerged as an important tool in the drug development process, as it conducts efficient in silico searches over millions of compounds, ultimately increasing yields of potential drug leads. As a subset of Artificial Intelligence (AI), Machine Learning (ML) is a powerful way of conducting VS for drug leads. ML for VS generally involves assembling a filtered training set of compounds, comprised of known actives and inactives. After training the model, it is validated and, if sufficiently accurate, used on previously unseen databases to screen for novel compounds with desired drug target binding activity.
Objective: The study aims to review ML-based methods used for VS and applications to Alzheimer’s Disease (AD) drug discovery.
Methods: To update the current knowledge on ML for VS, we review thorough backgrounds, explanations, and VS applications of the following ML techniques: Naïve Bayes (NB), k-Nearest Neighbors (kNN), Support Vector Machines (SVM), Random Forests (RF), and Artificial Neural Networks (ANN).
Results: All techniques have found success in VS, but the future of VS is likely to lean more largely toward the use of neural networks – and more specifically, Convolutional Neural Networks (CNN), which are a subset of ANN that utilize convolution. We additionally conceptualize a work flow for conducting ML-based VS for potential therapeutics for AD, a complex neurodegenerative disease with no known cure and prevention. This both serves as an example of how to apply the concepts introduced earlier in the review and as a potential workflow for future implementation.
Conclusion: Different ML techniques are powerful tools for VS, and they have advantages and disadvantages albeit. ML-based VS can be applied to AD drug development.
Export Options
About this article
Cite this article as:
Carpenter A. Kristy and Huang Xudong*, Machine Learning-based Virtual Screening and Its Applications to Alzheimer’s Drug Discovery: A Review, Current Pharmaceutical Design 2018; 24 (28) . https://dx.doi.org/10.2174/1381612824666180607124038
DOI https://dx.doi.org/10.2174/1381612824666180607124038 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Visible Light-Induced Photocatalytic Elimination of Organic Pollutants by TiO<sub>2</sub>: A Review
Current Organic Chemistry Novel Automated Method for the Detection of White Matter Hyperintensities in Brain Multispectral MR Images
Current Medical Imaging Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs
Current Psychiatry Research and Reviews Microendophenotypes of Psychiatric Disorders: Phenotypes of Psychiatric Disorders at the Level of Molecular Dynamics, Synapses, Neurons, and Neural Circuits
Current Molecular Medicine The Patient-centered Medical Home as an Intervention Strategy for Diabetes Mellitus: A Systematic Review of the Literature
Current Diabetes Reviews Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives
Current Alzheimer Research The Alzheimer's Disease-Related Glucose Metabolic Brain Pattern
Current Alzheimer Research Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research Oxidative Damage, Protein Synthesis, and Protein Degradation in Alzheimers Disease
Current Alzheimer Research Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules
Current Topics in Medicinal Chemistry The Immunoregulatory Activity of Mesenchymal Stem Cells: ‘State of Art’ and ‘Future Avenues’
Current Medicinal Chemistry Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets Selective Estrogen Receptor Modulators (SERMs): Effects on Multiple Organ Systems
Current Medicinal Chemistry Current Psychopharmacology of Obsessive-Compulsive Spectrum Disorders
Current Neuropharmacology Differentiation of Glioblastoma and Lymphoma Using Feature Extraction and Support Vector Machine
CNS & Neurological Disorders - Drug Targets Chemistry of Small Molecule Inhibitors in Self-Assembly of Alzheimers Disease Related Amyloid-Beta Peptide
Current Bioactive Compounds Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Peripheral Corticotropin Releasing Factor Signaling Inhibits Gastric Emptying: Mechanisms of Action and Role in Stress-related Gastric Alterations of Motor Function
Current Pharmaceutical Design